- Initial focus on non-diagnostic testing with Next Generation
Sequencing (NGS) for infection control, outbreak management and
research
- First commercial orders received and processed
Vienna, Austria, and Holzgerlingen,
Germany, August 08, 2019, 08:00 am CET - Curetis N.V. (the
"Company" and, together with its subsidiaries,
"Curetis"), a developer of next-level molecular diagnostic
solutions, today announced that its wholly-owned subsidiary Ares
Genetics GmbH has opened a specialized service laboratory offering
next-generation molecular antimicrobial resistance (AMR) testing
services with an initial focus on infection control, AMR
epidemiology and surveillance, clinical research and pharmaceutical
anti-infectives R&D. All services are based on Next Generation
Sequencing (NGS) and the company’s proprietary, AI-powered
antimicrobial resistance database ARESdb. The newly opened
laboratory is located at the Vienna Biocenter Campus in Vienna,
Austria, and will serve researchers, hospitals, public health
institutions, and pharmaceutical companies world-wide.
As a first offering, the laboratory will provide
whole genome sequencing of bacterial isolates for pathogen
identification, typing, and drug resistance detection under the
brand name ARESupa – Universal Pathogenome Assay. Next-generation
sequencing (NGS) data generated by ARESupa is analyzed,
interpreted, and reported through a cloud-based data interpretation
reporting system that builds on ARESdb. ARESdb compiles
high-resolution information on the genetics of antimicrobial
resistance mechanisms. At present, ARESdb covers the genomes of
about 40,000 bacterial strains and susceptibility data of more than
100 different antibiotics. Via the ARESupa test report, customers
can interactively explore detailed information on the identity of
pathogens as well as their genetic mechanisms of resistance, the
prevalence of such mechanisms and the accuracy with which they
predict resistance to specific antibiotics using Ares Genetics’
cloud-based data analytics platform.
With ARESupa, Ares Genetics aims at supporting
the cost-effective analysis and management of outbreaks of
multidrug-resistant bacterial pathogens in hospitals and care
facilities as well as facilitating antimicrobial drug development
and AMR research.
“With the opening of our laboratory in Vienna
and the first commercial orders for ARESupa, Ares Genetics delivers
on its transformation from an AMR data intelligence company to an
end-to-end service provider in AI-powered molecular drug resistance
testing,” said Dr. Andreas Posch, Managing Director and CEO of Ares
Genetics. “We are particularly grateful to our partners QIAGEN and
MGI as well as to the colleagues at the Vienna BioCenter, the
Austrian Research Promotion Agency and the Vienna Business Agency
who have supported us in setting up the laboratory to further scale
our business.”
“We believe that our offering of non-diagnostic
drug resistance testing services combining NGS with AI comes at the
right point in time, as key stakeholders in healthcare and public
health institutions increasingly advocate for the use of NGS
technology in epidemiology and outbreak management,” added Dr.
Achim Plum, Chief Business Officer of Curetis and Managing Director
of Ares Genetics. “Taking the concept further, we are also working
on first NGS-based human diagnostic applications in severe
infectious disease indications that are inadequately addressed by
current diagnostic practice.”
###ARESlab Services
For further information and quotes, please register
on the Ares Genetics cloud platform:
https://ares-genetics.cloud/
or contact
Ares Genetics GmbH Karl-Farkas-Gasse 18 A-1030 Wien
Austria
Email: services@ares-genetics.com About
Curetis
Curetis N.V.’s (Euronext: CURE) goal is to
become a leading provider of innovative solutions for molecular
microbiology diagnostics designed to address the global challenge
of detecting severe infectious diseases and identifying antibiotic
resistances in hospitalized patients.
Curetis’ Unyvero System is a versatile, fast and
highly automated molecular diagnostic platform for easy-to-use,
cartridge-based solutions for the comprehensive and rapid detection
of pathogens and antimicrobial resistance markers in a range of
severe infectious disease indications. Results are available within
hours, a process that can take days or even weeks if performed with
standard diagnostic procedures, thereby facilitating improved
patient outcomes, stringent antibiotic stewardship and
health-economic benefits. Unyvero in vitro diagnostic (IVD)
products are marketed in Europe, the Middle East, Asia and the
U.S.
Curetis’ wholly owned subsidiary Ares Genetics
GmbH is developing next-generation solutions for infectious disease
diagnostics and therapeutics. The ARES Technology Platform combines
the presumably most comprehensive database worldwide on the
genetics of antimicrobial resistances, ARESdb, with advanced
bioinformatics and artificial intelligence.
For further information, please visit
www.curetis.com and www.ares-genetics.com.
Legal Disclaimer
This document constitutes neither an offer to
buy nor to subscribe securities and neither this document nor any
part of it should form the basis of any investment decision in
Curetis.
The information contained in this press release
has been carefully prepared. However, Curetis bears and assumes no
liability of whatever kind for the correctness and completeness of
the information provided herein. Curetis does not assume an
obligation of whatever kind to update or correct information
contained in this press release whether as a result of new
information, future events or for other reasons.
This press release includes statements that are,
or may be deemed to be, “forward-looking statements”. These
forward-looking statements can be identified by the use of
forward-looking terminology, including the terms “believes”,
“estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or
“should”, and include statements Curetis makes concerning the
intended results of its strategy. By their nature, forward-looking
statements involve risks and uncertainties and readers are
cautioned that any such forward-looking statements are not
guarantees of future performance. Curetis’ actual results may
differ materially from those predicted by the forward-looking
statements. Curetis undertakes no obligation to publicly update or
revise forward-looking statements, except as may be required by
law.
Contact Details
Curetis GmbHMax-Eyth-Str.
4271088 Holzgerlingen, GermanyTel. +49 7031 49195-10pr@curetis.com
or ir@curetis.comwww.curetis.com
Curetis International Media &
Investor InquiriesakampionDr. Ludger Wess / Ines-Regina
Buth Managing Partnersinfo@akampion.comTel. +49 40 88 16 59 64Tel.
+49 30 23 63 27 68
- 20190808_PR_ARESlab_Opening_Final_Approved
Direxion Daily Healthcar... (AMEX:CURE)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Direxion Daily Healthcar... (AMEX:CURE)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
